Join our daily newsletter At The Bell to receive exclusive market insights
- Firebrick Pharma (FRE) reports its patent covering the formulation of its Nasodine nasal spray has been accepted in Australia
- The first “composition patent” for the product, valid until June 2041, covers the pharmaceutical composition of the Nasodine formulation regardless of the intended use or site of application
- Firebrick plans to also file the patent in the US, Europe and several other key markets
- Shares in Firebrick are up 14.89 per cent and trading at 27 cents at 3:54 pm AEDT
Firebrick Pharma (FRE) has reported its patent covering the formulation of its Nasodine nasal spray has been accepted in Australia.
The patent is valid until June 2041, and Firebrick said it planned to also file the patent in the US, Europe and several other key markets.
Executive Chairman Peter Molloy said the acceptance of the patent was an “important development” for Firebrick because it gave the company its first “composition patent” for Nasodine.
The new patent covers the pharmaceutical composition of the Nasodine formulation regardless of the intended use or site of application.
“If ultimately granted in the US and Europe, this patent significantly extends the patent protection around Nasodine and should make it more valuable for partnering, in my view,” Dr Molloy said.
The basis for the invention claimed in the patent is that the proprietary Nasodine formulation displays enhanced virucidal activity compared with PVP-I solutions alone, particularly with human rhinovirus (HRV), which is the main cause of the common cold.
The patent also discloses that based on independent in vitro studies, the Nasodine formulation has enhanced antiviral activity against SARS-CoV-2 (COVID-19 virus), when compared with aqueous PVP-I solution.
Shares in Firebrick were up 14.89 per cent and trading at 27 cents at 3:54 pm AEDT.
